Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Schlafen family member 14 (SLFN14) is an endoribonuclease and member of the Schlafen protein family implicated in RNA metabolism, immune defense, and human disease[1][2][3]. Structurally, SLFN14 consists of an RNase domain, a SWADL (Schlafen) domain, and a helicase-like C-terminal domain but lacks canonical helicase activity due to defective ATP binding[1]. SLFN14 binds and cleaves rRNA and ribosome-associated mRNAs, impacting protein translation[1][2][4]. Its normal function includes roles in the innate immune response and the development and secretion of platelets, explaining why mutations in SLFN14 cause inherited thrombocytopenia and bleeding disorders such as BDPLT20[1][2]. SLFN14 is also structurally related to other Schlafen proteins with important functions in cancer biology and immune defense, though its direct role as a therapeutic target is emerging primarily from genetic and structural studies rather than pharmacologic intervention[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Schlafen family member 14 (SLFN14).